The obesity duopoly has been pierced as Amgen positions itself to have a drug on the market in a few years. While this adds ...

Few companies garner as much reliable attention as Novo Nordisk (NYSE: NVO) does these days. With a bull market coinciding ...

Novo Nordisk faces challenges in weight-loss sector, but acquisition and strong diabetes portfolio position it for future ...

Patients in China will be able to purchase the blockbuster weight-loss drug Wegovy for 1,400 yuan, or about $193, just a ...

In the subsequent 5 years to follow, Novo Nordisk’s newest products, presently in FDA trials, are targeting the obesity market. It is anticipated to reach $100 billion by 2030. Obesity drugs ...

Doctors Without Borders (MSF) and organisations representing people with diabetes picketed outside the offices of insulin ...

Doctors Without Borders, also known as Médecins Sans Frontières (MSF), and organisations representing people with diabetes ...

UBS analyst Jo Walton maintained a Hold rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK1,100.00. The company’s shares ... In comparison, last year the company ...

The plans from the Department of Health and Human Services come on the heels of criticism Ozempic and other weight loss ...